The Indian Practitioner

K. R. Meghanadh ¹, Mandeep Kaur ², Deepak Haldipur ³, Charuhas Jagtap ⁴, N. K. Soni ⁵, Ashwin Kotamkar ⁶, Aaditi Phadke ⁶, Parthasarathy Muralidharan ⁶, Amit Qamra ⁶

Affiliations
1 Department Otorhinolaryngology and Head and Neck Surgery, MAA ENT Hospital, Hyderabad, IN
2 Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, IN
3 Department of ENT, Trustwell Hospitals, Bangalore, IN
4 Department of ENT, Jagtap Hospital, Dhule, IN
5 Department of Internal Medicine & Diabetology, Yatharth Super Speciality Hospital, Greater Noida, IN
6 Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, IN

Abstract

Recurrent aphthous stomatitis (RAS) is one of the commonly observed disease of the oral cavity and the prevalence ranges from 5 to 60%. Despite its high prevalence, the exact pathophysiology of the disease remains unknown. Multiple etiologic factors, followed by three stages of the disease, and types based on severity, with addition of pain and inflammation makes the management challenging for the clinician. A number of drugs are available for the treatment having their own advantages and limitations. In this narrative review, we review the available Indian evidence with Rebamipide in RAS. Indian clinical evidence clearly establishes the safety and efficacy of rebamipide in the management of RAS. Thus, considering the benefits of reduced duration of pain, accelerated healing and decreased recurrence, we conclude that the current Indian evidence supported by our clinical experience establishes the role of Rebamipide in RAS. Hence, we recommend Rebamipide may be considered as a first line treatment option in RAS.

Keywords

Recurrent Aphthous Stomatitis, Rebamipide.

Full Text